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Amiodarone-induced pulmonary toxicity (APT) is a serious adverse event that can lead to
death. The aims of our study are to determine factors associated with mortality and to
describe outcome and sequelae of patients with APT.
Methods: Forty-six patients with APT were divided into two groups according to survival at day
90 for a clinical, functional, biological and radiological comparaison. We then evaluated the
evolution of 15 survivors at a median of three months [1e6 months] and/or 12 months [8
e36 months].
Results: Mortality of APT at day 90 was 37% (17 patients) and was linked to the speed of onset
of symptoms and a high HRCT alveolar score. Angiotensin system antagonist treatment was
prescribed significantly more in the survival group (p Z 0.042, HR 0.34 (95% CI 0.12e0.96)).
In surviving patients, dyspnea, vital capacity and HRCT alveolar score improved significantly
while HRCT fibrosis score deteriorated gradually during the first six months. At the end of
the study, all the surviving patients presented functional and/or radiological sequelae.uced pulmonary toxicity; ARDS, Acute Respiratory Distress Syndrome; ASA, angiotensin system
ge; BMI, body mass index; DEA, N-desethylamiodarone; HRCT, high resolution computer tomography;
ncil; PFT, pulmonary function tests.
Pneumologie et explorations fonctionnelles respiratoire, Hoˆpital Bretonneau, 2 boulevard Tonnelle´,
2 47473787; fax: þ33 2 47473882.
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Amiodarone-induced pulmonary toxicity 639Conclusions: Severity of APT is linked to the extent and speed of onset of pulmonary damage.
After the initial episode, the patients who survived improved slowly but with persistent
sequelae.
ª 2014 Elsevier Ltd. All rights reserved.Amiodarone is one of the most commonly prescribed anti-
arrhythmic drugs and is considered the most effective.
Amiodarone-induced pulmonary toxicity (APT) occurs in
0.1e17% [1] of cases, with mortality ranging from 1 to 50%
when Acute Respiratory Distress Syndrome (ARDS) develops
[2e4]. Several mechanisms have been proposed to explain
this toxicity [2,5e9]: direct drug-induced phospholipidosis
secondary to lysosomal phospholipase inhibition and phos-
pholipid accumulation due to the amphiphilic properties of
amiodarone’s metabolite, N-desethylamiodarone (DEA). DEA
concentrates inorganswithhigh lipid content, suchasadipose
tissue, the thyroid, liver and lungs. The clinical manifestation
of phospholipidosis is the presence of foamy cells in bron-
choalveolar lavage (BAL). However, foamy cells are not spe-
cific for amiodarone pulmonary toxicity and are currently
considered merely to reflect the effect of a drug. An immu-
nological hypothesis can also be put forward, based on the
observation of T-cell infiltrates in some patients [7,10e12].
A dose-dependent effect was initially described, and
high cumulative dose, high daily dosage (>400 mg/d) and
duration of therapy (>12 months) are commonly recognized
risk factors for pulmonary toxicity. However, some recent
publications have reported toxicity with lower amiodarone
doses or after only a few weeks of amiodarone therapy
[13e16]. Many other risk factors have been described for
amiodarone lung toxicity, notably age, but also male
gender, pre-existing lung disease, renal disease, surgery,
and high concentrations of inspired oxygen [3,17e24].
Clinical practice suggests that the outcome of APT after the
initial episode is favorable after discontinuation of amio-
darone, with or without corticosteroids [25].
To our knowledge, no study has evaluated the factors
associated with mortality and pulmonary sequelae of APT.
The aims of our retrospective study in patients with APT
were to determine factors associated with mortality and to
describe the medium- and long-term clinical, physiological
and radiological pulmonary outcomes.Figure 1 Patient flow-chart.Methods
Patients
Our study was retrospectively conducted in the respiratory
medicine department and intensive care unit of the uni-
versity hospital of Tours, France. We reviewed 101 cases of
drug-induced pulmonary toxicity among patients hospital-
ized between January 2000 and August 2011 (Fig. 1). Fifty-
five patients were excluded, 43 because they had not
received amiodarone during the previous month and 12
because of insufficient data to establish the diagnosis of
APT.
French legislation does not require the agreement of an
ethics committee, nor the informed consent of patients, forthe retrospective collection of data that conform to current
practice. However, the study protocol was evaluated and
approved by the Institutional review board of the French
Society for Respiratory Medicine (Socie´te´ de Pneumologie
de Langue Franc¸aise) (CEPRO 2011-031). The database was
anonymous and complied with the restrictive requirements
of the Commission Nationale de l’Informatique et des
Liberte´s, the organization that ensures the application of
data privacy laws in France.
Forty-six patients were diagnosed as having APT based
on intrinsic and extrinsic pharmacological imputability
criteria. The diagnosis criteria of APT were: a/amiodarone
treatment at the time of diagnosis, b/new or worsening
respiratory symptoms, c/new pulmonary infiltrates on chest
radiography or high-resolution computed tomography
(HRCT), d/exclusion of differential alternatives (cardio-
genic edema, sepsis, other drug-induced pulmonary dis-
eases), and e/improvement shown by surviving patients
after amiodarone withdrawal, with or without
corticosteroids.Initial investigations
We collected the following data from the medical file of
each patient: age, sex, body mass index (BMI), duration of
Table 1 Baseline characteristics of surviving and non-surviving patients with amiodarone pulmonary toxicity. All quantitative
data are expressed as median [range] values.
Survival (n Z 29) Non-survival (n Z 17) p
Baseline characteristics
Age in years 80 [54; 93] 82 [66; 94] 0.569
Sex ratio M/F 19/10 10/7 0.650
BMI, Kg/m2 25 [18; 34] 25 [16; 31] 0.897
Current smokers 6 6 0.521
Smokers, n 5 3
Non-smokers n 18 8
Chronic respiratory failure, n (%) 2/18 (11%) 0/3 (0%) 1.000
Chronic cardiac failure, n (%) 13/25 (52%) 7/12 (58%) 1.000
Chronic dyspnea before APT, MMRC 1 [0; 3] 0 [0; 3] 0.225
Diabetes, n (%) 4/14 (29%) 1/3 (33%) 1.000
Gastroesophogeal reflux, n (%) 3/15 (20%) 0/3 (0%) 1.000
Amiodarone total cumulative dose, gr 109 [10; 720] 77 [4; 257] 0.215
Duration of amiodarone therapy in months 22 [1; 120] 16 [1; 60] 0.364
ASA treatment, n (%) 22/28 (79%) 8/17 (47%) 0.048
Initial clinical data
Time between first symptoms and
hospitalization in weeks
4 [1; 32] 2 [1; 12] 0.003
Time between first symptoms and
withdrawal of amiodarone in days
14 [1; 71] 6 [2; 24] 0.026
Acute dyspnea, NYHA 4 [2; 4] 4 [4; 4] 0.007
Fever, n (%) 21/29 (72%) 10/17 (59%) 0.342
Cough, n (%) 24/29 (38%) 9/17 (53%) 0.417
Sputum, n (%) 12/29 (41%) 8/17 (47%) 0.708
Hemoptysis, n (%) 4/29 (14%) 2/17 (12%) 1.000
PaO2/FiO2 ratio, mmHg 214 [39; 371] 110 [43; 219] 0.024
Treatment modalities
Corticosteroid treatment, n (%) 22 (76%) 16 (94%) 0.226
ICU admission, n (%) 16 (55%) 9 (53%) 0.883
Mechanical ventilation, n (%) 11 (38%) 8 (47%) 0.609
640 J. Mankikian et al.therapy, cumulative dose, angiotensin system antagonist
(ASA) treatment, time between onset of symptoms and
hospitalization and between hospitalization and APT diag-
nosis, clinical data (cough, dyspnea, .), biological data
(PaO2/FiO2 rate, BAL,...), ICU admission, treatment mo-
dalities (mechanical ventilation, steroids) and pulmonary
function test (PFT, see method in the Online Data
Supplement).
All patients underwent HRCT of the lung at baseline.
Ground-glass opacities and alveolar consolidations were
quantified to give an active lesion score (or HRCT alveolar
score), while traction bronchiectasis, scissural distortions
and honeycombing were considered to represent fibrotic
lesions and were quantified to produce an HRCT fibrosis
score (see method in the Online Data Supplement).Patient follow-up after initial hospitalization
For 15 of the 29 surviving patients we compared clinical
(dyspnea), physiological and radiological data at medium
term (median 3 months, range 1e6 months, after APT
diagnosis) and/or long term (median 12 months, range
8e36 months, after APT diagnosis) with initial data. Theother 14 surviving patients were lost or data were insuf-
ficient. The clinical features of lost patients did not differ
from those of followed-up patients, except that they were
older (e-Table 1 in Online Data Supplement). Among 15
followed patients, there was no difference in clinical,
functional and radiological characteristics in the long
term between older and younger patients (data not
shown).Statistical analysis
A non-parametric method was used, and all data are
expressed as median [range] values. The Mann Whitney test
was performed to compare survival and non-survival
groups. Chi-Squared and Fischer tests were used to
compare category data for each group. Survival curves were
constructed using the KaplaneMeier method with a statis-
tical comparison based on the log-rank test. The Wilcoxon
signed-rank test was performed to evaluate the significance
of clinical, physiological and radiological changes between
baseline and follow-up. The correlations were assessed
with the Spearman’s rank-order test. Statistical significance
was defined as a p-value of <0.05.
Figure 2 KaplaneMeier Estimates of survival among patients
with amiodarone-induced pneumonia (APT). Patients treated
with angiotensin system antagonist (ASA) presented a relative
protection against APT.
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Baseline characteristics
Clinical data (Table 1)
We selected 46 patients with diagnostic criteria for APT
based on intrinsic and extrinsic pharmacological imput-
ability. Amiodarone had been prescribed in 45 patients for
atrial fibrillation and in one patient for ventricular
arrhythmia. Patients were divided into two groups accord-
ing to survival at 90 days. For the seventeen patients in the
non-survival group (37%), median time of death was the
seventeenth day of hospitalization [3e65 days after
admission]; Ten died of amiodarone-induced ARDS, 6 pa-
tients died of multiple organ failure (one septic shock, oneTable 2 HRCT characteristics of surviving and non-surviving
opacities and alveolar consolidations were quantified to give an
bronchiectasis, scissural distortions and honeycombing were con
produce an HRCT fibrosis score. Six areas of the lung were defined
section HRCTwas scored semi-quantitatively: 1Z less than 25% of
4 Z more than 75%, yielding a total score (total: 0e24). The othe
data are expressed as median [range] values.
HRCT score Survival (n Z
Alveolar score (/24)
upper areas 5 [2; 8]
middle areas 6 [2; 7]
inferior areas 6 [2; 8]
Total 18 [8; 23]
upper/lower gradient 1 [5; 4]
Total fibrosis score (/24) 2 [0; 5]
Adenopathy, n (%) 13 (59%)
Pleural effusion, n (%) 5 (23%)
Interlobular septa thickening, n (%) 15 (68%)
Intralobular reticulation, n (%) 20 (91%)
Crazy paving, n (%) 16 (73%)
Lobular attenuation, n (%) 15 (68%)exacerbation of cirrhosis, four patients with multiple
comorbidities after opting for palliative care), 1 patient
died of herpetic meningitis after corticotherapy. The cu-
mulative dose and duration of amiodarone therapy did not
differ significantly between the two groups, nor age, sex
ratio, BMI, pulmonary or cardiac co-morbidities. Angio-
tensin system antagonist (ASA) treatment had been pre-
scribed significantly more in the survival group (pZ 0.042,
HR 0.34 (95% CI 0.12e0.96)) (Fig. 2).
Clinical features did not differ between the two groups
(fever, asthenia, chest pain, cough, sputum, hemoptysis),
except that symptoms occurred earlier (3 weeks [1,21]
versus 7 weeks [3; 42], p Z 0.003) and dyspnea was more
severe (p Z 0.007) in the non-survival group.
Biological findings (Table 1)
Apart from a lower PaO2/FiO2 ratio in the non-survival
group (pZ 0.024), no other biological data were predictive
of mortality. There was no significant difference in BAL
bacterial culture or cell fraction (n Z 28, e-Table 2 in
Online Data Supplement).
Pulmonary function tests
Initial pulmonary function tests could not be performed in
34 patients because of the severity of respiratory failure.
Tests were performed in 12 patients in the survival group
and none in the non-survival group. Median TLC was 78%
[58%; 91%] and VC 74% [58%; 96%]. Six patients had a
restrictive syndrome defined by TLC <80%. DLCO was
assessed in seven patients and was low in six patients (45%
[32%; 87%]).
HRCT (Table 2)
HRCT was performed in 22 patients (76%) in the survival
group and 13 patients (76%) in the non-survival group, at a
median of 3e5 days following admission. In all patients we
found diffuse and bilateral ground-glass opacities withpatients with amiodarone pulmonary toxicity. Ground-glass
active lesion score (or HRCT alveolar score), while traction
sidered to represent fibrotic lesions and were quantified to
: the upper, middle and lower zones. Opacity intensity on thin
total lung parenchyma in the area, 2Z 25e50%, 3Z 50e75%,
r HRCT abnormalities were noted if present. All quantitative
22) Non-survival (n Z 13) P
7 [4; 8] 0.006
7 [6; 8] 0.008
6 [4; 8] 0.972
20 [17; 23] 0.004
1 [3; 5] 0.061
0 [0; 4] 0.149
6 (46%) 0.458
7 (54%) 0.079
10 (77%) 0.709
10 (77%) 0.337
10 (77%) 0.680
9 (69%) 0.630
Figure 3 Outcomes of amiodarone pulmonary toxicity: clinical (MMRC dyspnea scale, Fig. 3a) and functional improvement
(Fig. 3b, c, d) between the initial assessment, the medium-term (1e6 months) and long-term evaluation (8e36 months). Closed
circles: patients with corticotherapy. Open circles: patients without corticotherapy. Individual values and median (bar). *p < 0.05
medium-term versus initial scores, yp < 0.05 long-term versus medium-term scores, $ p < 0.05 long-term versus initial scores.
642 J. Mankikian et al.alveolar consolidation (Fig. 4a). The HRCT alveolar score
was significantly higher in the non-survival than the survival
group (20 [17,23] versus 18 [8,23], p Z 0.004), with more
homogeneous distribution (p Z 0.004). PaO2/FiO2 ratio
was inversely correlated with the HRCT alveolar score
(Rho Z 0.692, p Z 0.001). The other abnormalities
(fibrotic lesions, lymphadenopathies, pleural effusion,
lobular attenuation, reticulation) did not differ significantly
between the two groups.
Initial treatment
There were no differences concerning ICU admission and
mechanical ventilation. The APT diagnosis was made at a
median of three days post-admission. After diagnosis,
amiodarone was stopped. Corticosteroids were adminis-
tered to 83% of the patients at a median dose of 1 mg/kg
[0.5e5 mg/kg] with no difference between the two
groups.Follow-up
Clinical and physiological data
We followed up 15 surviving patients. Amiodarone was
withdrawn in all cases and 60% of patients were given
corticosteroids for an initial duration of 3e29 months. The
three patients treated for less than three months relapsed
and corticosteroid treatment was renewed. No relapse was
observed among patients treated for more than six months.
After initial diagnosis of APT, clinical, physiological and
HRCT assessments were carried out at medium term (me-
dian 3 months, range 1e6 months, after APT diagnosis)and/or long term (median 12 months, range 8e36 months,
after APT diagnosis).
In all 15 cases, cough, fever and asthenia disappeared
during the first six months (at medium term). Dyspnea
partially improved, with median MMRC (Modified Medical
Research Council) dyspnea scale decreasing from 4 to 2
(pZ 0.008). At long term, all but two patients were at their
previous level of dyspnea (no dyspnea in three cases) (Table
3 and Fig. 3).
VC improved significantly at medium term and at long
term. TLC and DLCO improved, but not significantly. At the
end of the study, five patients had a persistent restrictive
syndrome. PaO2/FiO2 ratio significantly improved in the
first few months (at medium term), increasing from
238 mmHg to 419 mmHg (Fig. 3). PaO2 was not evaluated
after four months of APT diagnosis.
HRCT data (Table 4)
An improvement in alveolar opacities was observed at
medium term, with HRCT alveolar score decreasing by more
than 40% (p Z 0.05), and continued at long term without
normalization. Fibrotic lesions were observed at APT diag-
nosis in 10 of the 15 patients, with a progressive and
moderate, but significant (p < 0.05), increase mainly at
medium term. Lesions consisted mainly of traction bron-
chiectasis and scissural distortions. We found honey-
combing lesions (not suggestive of the usual interstitial
pneumonia pattern) in only one case in whom no other lung
fibrosis etiology was found. The other initial abnormalities
(reticulation, lobular attenuation, pleural effusion and
adenopathy) improved. None of the patients had normal-
ized their CT-scan at long term.
Figure 4 Representative HRCT scan of amiodarone-induced pneumonia in an 88-year-old patient at diagnosis (Fig. 4a) and 10.5
months after discontinuation of amiodarone with 6 months of corticosteroid therapy (Fig. 4b). HRCT alveolar (Fig. 4c) and fibrosis
(Fig. 4d) score improvements between initial assessment, medium-term (1e6 months) and long-term (8e36 months) evaluation.
Closed circles: patients with corticotherapy. Open circles: patients without corticotherapy. Individual values and median (bar).
*p < 0.05 medium-term versus initial scores, yp < 0.05 long-term versus medium-term scores, $ p < 0.05 long-term versus initial
scores.
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Nine of the 15 patients (60%) received corticosteroid ther-
apy and amiodarone was stopped in all cases. Treated-
patients had a more severe APT (PaO2/FiO2 and alveolitis
score) with greater improvement of their MMRC score
(pZ 0.007) and VC (pZ 0.02) than non-treated patients at
long term, but there was no difference in HRCT evolution.Discussion
In our study, 17 patients (37%) with APT died during hos-
pitalization. The rapid onset of the clinical picture, theTable 3 Pulmonary function characteristics between initial asse
(8e36 months) All quantitative data are expressed as median [ra
Pulmonary function characteristics Initial evaluation
MMRC 4 [2; 4] (n Z 15)
FEV1, % of predictive value 84 [63; 96] (n Z 11)
FEV1/VC , % of predictive value 81 [69; 99] (n Z 11)
VC, % of predictive value 74 [58; 96] (n Z 11)
TLC, % of predictive value 78 [58; 91] (n Z 11)
DLCO, % of predictive value 45 [32; 87] (n Z 7)
KCO, % of predictive value 83 [44; 150] (n Z 7)
PaO2/FiO2, mmHg 238 [42; 371] (n Z 15initial severity (PaO2/FiO2), the extent of lung injury on
HRCT, and the homogeneous distribution were poor prog-
nostic factors. Conversely, ASA treatment appeared as a
potentially protective factor. Furthermore, all the patients
who initially survived APT showed clinical, functional and
radiological improvement when amiodarone was with-
drawn, with or without corticosteroids. This improvement
was slow and extended beyond six months after initial
support. However, physiological and/or radiological
sequelae were observed in all patients.
There is no clinical, physiological, biological or radio-
logical gold standard to diagnose APT. In our patients, a
diagnosis of APT was made based on intrinsic and extrinsicssment, medium-term (1e6 months) and long-term evaluation
nge] values.
2nd evaluation 3rd Evaluation
2 [0; 3](n Z 15) 1 [0; 2] (n Z 13)
85 [58; 126] (n Z 12) 93 [73; 132] (n Z 12)
78 [71; 99] (n Z 12) 79 [65; 90](n Z 12)
79 [50; 117] (n Z 12) 95 [68; 122] (n Z 12)
78 [66; 90] (n Z 10) 84 [70; 102] (n Z 11)
46 [31; 67](n Z 11) 58 [37; 81] (n Z 8)
86 [50; 129] (n Z 11) 88 [56; 130] (n Z 8)
) 419 [243; 457](n Z 8) NA
Table 4 HRCT characteristics between initial assessment, mid-term (1e6 months) and long-term evaluation (8e36 months).
Ground-glass opacities and alveolar consolidations were quantified to give an active lesion score (or HRCT alveolar score), while
traction bronchiectasis, scissural distortions and honeycombing were considered to represent fibrotic lesions and were quan-
tified to produce an HRCT fibrosis score Six areas of the lung were defined: the upper, middle and lower zones. Opacity intensity
on thin section HRCT was scored semi-quantitatively: 1 Z less than 25% of total lung parenchyma in the area, 2 Z 25e50%,
3Z 50e75%, 4Z more than 75%, yielding a total score (total: 0e24). The other HRCT abnormalities were noted if present. All
quantitative data are expressed as median [range] values.
HRCT score Initial (n Z 15) 1 to 6 months (n Z 12) 8 to 36 months (n Z 14)
HRCT leadtime (months) 0.1 [0,03; 0,86] 2.5 [1; 6] 26 [8; 36]
Alveolar score (/24) 17 [8; 24] 10 [1; 19] 7 [1; 13]
Fibrosis score (/24) 2 [0; 5] 4 [1; 5] 4 [0; 9]
Adenopathy, n (%) 9 (60%) 6 (50%) 4 (28%)
Pleural effusion, n (%) 5 (33%) 2 (17%) 1 (7%)
Interlobular septa thickening, n (%) 14 (93%) 11(92%) 10 (71%)
Intralobular reticulation, n (%) 15 (100%) 10 (83%) 12 (86%)
Crazy paving, n (%) 12 (80%) 6 (50%) 4 (28%)
Lobular attenuation, n (%) 12 (80%) 8 (67%) 7 (50%)
644 J. Mankikian et al.imputability criteria, as is the rule with any drug-induced
adverse effect.
There are several clinical presentations of APT: a chronic
form, indolent with few or no symptoms, a sub-acute form
which is the most common, and rarely ARDS. Our patients
mainly presented sub-acute forms. Seventeen patients died
during their hospitalization (37%) including 9 from
amiodarone-induced ARDS, which is consistent with previ-
ously reported series [2]. Age and amiodarone exposure
(cumulative dose, daily dosage, and long-term therapy) are
the most widely published risk factors of amiodarone
toxicity [3,17e24]. No previous study has determined
prognosis factors. In our study, we found shorter clinical
onset and more severe hypoxemia in non-surviving patients.
This has been observed in cardiac surgery with the use of
intravenous amiodarone for the prevention of perioperative
arrhythmia [2,18]. This observation could support the hy-
pothesis of an allergic immune reaction against amiodarone
or its metabolites during severe APT. We observed that
patients treated with inhibitors of the renin-angiotensin
system had a lower risk of mortality. Some authors have
reported that these agents have a protective effect against
APT [26]. In vitro, apoptosis of alveolar epithelial cells
induced by amiodarone increases in the presence of
angiotensin II and is reduced by renin-angiotensin system
antagonists [26].
Many authors have studied the initial radiological man-
ifestations of APT [21,27e35]. The lesions are mainly non-
specific, with an alveolar syndrome involving ground-glass
opacities and alveolar consolidation. In our patients, the
extent of alveolar opacities was greater in the non-survival
group and was the only radiological criterion correlating
closely with the PaO2/FiO2 ratio and mortality. A correla-
tion between HRCT involvement and severity scores,
including PaO2/FiO2 ratio [36] and mortality [37,38] in in-
fectious and non-infectious ARDS, has previously been re-
ported. Other commonly observed opacities, such as
intralobular reticulations, thickening of the interlobular
septa, pleural effusions and signs of pulmonary fibrosis
(honeycombing and traction bronchiectasis) were found in
our study, but they were not prognostic factors.To our knowledge, our study is the first to report in a
semi-quantitative way the clinical, physiological and
radiological evolution of patients with APT. The improve-
ment of symptoms following withdrawal of amiodarone has
previously been described [25,31,35]. The respiratory
symptoms of our patients returned to normal at medium
term (1e6 months), except for dyspnea which continued to
improve between the second and third evaluation (at 1e3
months and 8e36 months respectively). At long term (8_ to
36 months), the dyspnea score of all but two patients
returned to their pre-APT score. The slow improvement of
the respiratory status of our patients is also reflected in the
physiological data, with a slight but significant improve-
ment of VC, TLC and DLCO after 8e36 months.
In our study, ground-glass opacities, consolidation, intra-
alveolar reticulations and pleural effusions improved after
withdrawal of amiodarone. Only a few case reports [31,34]
and one study [35] have examined HRCT evolution of APT
after amiodarone withdrawal. Vernhet et al. observed a
normalization of chest X-rays in 16 out of 20 patients. Only
one of the four patients who had an HRCT evaluation at
three months no longer had pulmonary opacities. However,
there is no information regarding the severity of APT.
After 8e36 months, patients retained a respiratory
disability characterized by dyspnea and a decrease in DLCO
(in 12 out of 15 patients). Residual radiological ground-glass
opacities, intralobular reticulations and signs of pulmonary
fibrosis observed at the third evaluation were localized
mainly in the initially most affected areas. Fibrosis score
was the only radiological parameter that worsened over
time, mainly in the first six months following withdrawal of
amiodarone.
Treatment with systemic corticosteroids was initiated
in 60% of surviving patients (9/15) for a period of 3e29
months. Corticosteroids are currently recommended for
6e12 months in patients with the most severe presenta-
tion or who show no improvement after stopping amio-
darone, with no evidence of any impact on mortality
[9,25]. In our study, corticosteroids were initiated in
more severe cases and had a positive effect on alveolar
opacities observed at APT diagnosis. Moreover, despite
Amiodarone-induced pulmonary toxicity 645corticosteroid therapy, the fibrosis score of some patients
increased at medium term (1e6 months). APT relapse was
observed when treatment lasted less than three months
but not when it lasted longer than six months. The long
half-life elimination of amiodarone (40e70 days) and its
storage in lung parenchyma probably explain the slow
improvement in APT and relapse within three months of
corticosteroid therapy [7].
This study has some limitations. First, because of its
retrospective nature, nearly half of the surviving patients
were lost, limiting the conclusions. Lost patients were
older, but there were no other baseline differences with
followed-up patients. They were probably lost because of
their age and the absence of the expected benefits of
repeated HRCT or functional tests. Among the 15 followed-
up patients, there were no long-term differences in clin-
ical, functional and radiological characteristics between
older and younger patients. There was also a selection bias
in that our study only included hospitalized patients, who
were probably more severe cases with higher mortality
rates than out-patients. Finally the main limitation is the
small sample size and a prospective study will be necessary
to confirm our observation.
APT mortality may be related to rapid onset and the
extent of lung injury. In patients who are treated for APT,
improvement is slow and extends beyond six months after
discontinuation of amiodarone, with or without systemic
corticosteroids. All patients presented functional and/or
radiological sequelae at 12 months. Further studies are
needed to evaluate the benefit of oral corticosteroids
following APT.Author contributions
Pr Marchand-Adam: had full access to all of the data in the
study and takes responsibility for the integrity of the data
and the accuracy of the data analysis.
Dr Mankikian: had full access to all of the data in the
study and contributed to the study design, data collection,
data analysis, and manuscript writing.
Dr Favelle: contributed to data collection, data analysis,
and manuscript writing.
Dr Guillon: contributed to the data collection, data
analysis, and manuscript writing.
Dr Guilleminault: contributed to the data collection,
data analysis, and manuscript writing.
Dr Cormier: contributed to the data collection, data
analysis, and manuscript writing.
Dr Jonville-Be´ra: contributed to the data collection,
data analysis, and manuscript writing.
Pr Perrotin: contributed to the data collection, data
analysis, and manuscript writing.
Pr Diot: contributed to the study design, data collection,
data analysis, and manuscript writing.Conflict of interest statements
All authors declare that there are no conflicts of interest.Acknowledgments
None.Appendix A. Supplementary data
Supplementary data related to this article can be found at
http://dx.doi.org/10.1016/j.rmed.2014.01.014References
[1] Vassallo P, Trohman RG. Prescribing amiodarone: an evidence-
based review of clinical indications. JAMA 2007;298(11):
1312e22.
[2] Ashrafian H, Davey P. Is amiodarone an underrecognized cause
of acute respiratory failure in the ICU? Chest 2001;120(1):
275e82.
[3] Martin WJ, Rosenow EC. Amiodarone pulmonary toxicity.
Recognition and pathogenesis (Part I). Chest 1988;93(5):
1067e75.
[4] Rakita L, Sobol SM, Mostow N, Vrobel T. Amiodarone pulmo-
nary toxicity. Am Heart J 1983;106(4 Pt 2):906e16.
[5] Anderson, Borlak. Drug-induced phospholipidosis. FEBS Lett
2006;580(23):5533e40.
[6] Bedrossian CW, Warren CJ, Ohar J, Bhan R. Amiodarone pul-
monary toxicity: cytopathology, ultrastructure, and immuno-
cytochemistry. Ann Diagn Pathol 1997;1(1):47e56.
[7] Martin, Rosenow. Amiodarone pulmonary toxicity. Recognition
and pathogenesis (Part 2). Chest 1988;93(6):1242e8.
[8] Papiris SA, Triantafillidou C, Kolilekas L, Markoulaki D,
Manali ED. Amiodarone: review of pulmonary effects and
toxicity. Drug Saf 2010;33(7):539e58.
[9] Vinsonneau U, Andre´ V, Brondex A, Andre´ M, Gondon P,
Arles F, Quiniou G. Pneumopathie a` l’amiodarone : physi-
opathologie et diagnostic. Arch Mal Coeur Vaiss 2008;14:17e9.
[10] Coudert B, Bailly F, Lombard JN, Andre F, Camus P. Amio-
darone pneumonitis. Bronchoalveolar lavage findings in 15
patients and review of the literature. Chest 1992;102(4):
1005e12.
[11] Nicolet-Chatelain G, Prevost MC, Escamilla R, Migueres J.
Amiodarone-induced pulmonary toxicity. immunoallergologic
tests and bronchoalveolar lavage phospholipid content. Chest
1991;99(2):363e9.
[12] Ohar JA, Jackson F, Dettenmeier PA, Bedrossian CW,
Tricomi SM, Evans RG. Bronchoalveolar lavage cell count and
differential are not reliable indicators of amiodarone-induced
pneumonitis. Chest 1992;102(4):999e1004.
[13] Jackevicius CA, Tom A, Essebag V, et al. Population-level
incidence and risk factors for pulmonary toxicity associated
with amiodarone. Am J Cardiol 2011;108(5):705e10.
[14] Ott MC, Khoor A, Leventhal JP, Paterick TE, Burger CD. Pul-
monary toxicity in patients receiving low-dose amiodarone.
Chest 2003;123(2):646e51.
[15] Yamada Y, Shiga T, Matsuda N, Hagiwara N, Kasanuki H. Inci-
dence and predictors of pulmonary toxicity in Japanese pa-
tients receiving low-dose amiodarone. Circ J 2007;71(10):
1610e6.
[16] Vorperian VR, Havighurst TC, Miller S, Junuary CT. Adverse
effects of low dose amiodarone: a meta-analysis. J Am Coll
Cardiol 1997;30:791e8.
[17] AFFIRM First Antiarrhythmic Drug Substudy Investigators.
Maintenance of sinus rhythm in patients with atrial fibrilla-
tion: an AFFIRM substudy of the first antiarrhythmic drug. J
Am Coll Cardiol 2003;42(1):20e9.
646 J. Mankikian et al.[18] Argyriou M, Hountis P, Antonopoulos N, Mathioudaki M. Acute
fatal post-CABG low dose amiodarone lung toxicity. Asian
Cardiovasc Thorac Ann 2007;15(6):66e8.
[19] Dimopoulou I, Marathias K, Daganou M, et al. Low-dose
amiodarone-related complications after cardiac operations. J
Thorac Cardiovasc Surg 1997;114(1):31e7.
[20] Ernawati DK, Stafford L, Hughes JD. Amiodarone-induced
pulmonary toxicity. Br J Clin Pharmacol 2008;66(1):82e7.
[21] Kudenchuk PJ, Pierson DJ, Greene HL, Graham EL, Sears GK,
Trobaugh GB. Prospective evaluation of amiodarone pulmo-
nary toxicity. Chest 1984;86(4):541e8.
[22] Mieghem WV, Coolen L, Malysse I, Lacquet LM, Deneffe GJ,
Demedts MG. Amiodarone and the development of ARDS after
lung surgery. Chest 1994;105(6):1642e5.
[23] Masatsugu N, Toshihiro H, Mitsuko H, Kazuya I, Moritaka S,
Koichi N. Smoking history and underlying lung disease are
associated with poor outcome in patients developing inter-
stitial pneumonia during low-dose amiodarone therapy. J
Arrhythmia 2013;29(1):5e8.
[24] Saussine M, Colson P, Alauzen M, Mary H. Postoperative acute
respiratory distress syndrome. A complication of amiodarone
associated with 100 percent oxygen ventilation. Chest 1992;
102(3):980e1.
[25] Goldschlager N, Epstein AE, Naccarelli GV, et al. A practical
guide for clinicians who treat patients with amiodarone: 2007.
Heart Rhythm 2007;4:1250e9.
[26] Nikaido A, Tada T, Nakamura K, et al. Clinical features of and
effects of angiotensin system antagonists on amiodarone-
induced pulmonary toxicity. Int J Cardiol 2010;40(3):328e35.
[27] Kennedy JI, Myers JL, Plumb VJ, Fulmer JD. Amiodarone
pulmonary toxicity. Clinical, radiologic, and pathologic cor-
relations. Arch Intern Med 1987;147(1):50e5.
[28] Kuhlman JE, Teigen C, Ren H, et al. Amiodarone pulmonary
toxicity: CT findings in symptomatic patients. Radiology 1990;
177(1):121e5.[29] Nicholson AA, Hayward C. The value of computed tomography
in the diagnosis of amiodarone-induced pulmonary toxicity.
Clin Radiol 1989;40(6):564e7.
[30] Oyama No, Oyama Na, Yokoshiki H, et al. Detection of
amiodarone-induced pulmonary toxicity in supine and prone
positions: high-resolution computed tomography study. Circ J
2005;69(4):466e70.
[31] Poll LW, May P, Koch JA, Hetzel G, Heering P, Mo¨dder U. HRCT
findings of amiodarone pulmonary toxicity: clinical and
radiologic regression. J Cardiovasc Pharmacol Ther 2001;6(3):
307e11.
[32] Rossi SE, Erasmus JJ, McAdams HP, Sporn TA, Goodman PC.
Pulmonary drug toxicity: radiologic and pathologic manifes-
tations. Radiographics 2000;20(5):1245e59.
[33] Siniakowicz RM, Narula D, Suster B, Steinberg JS. Diagnosis of
amiodarone pulmonary toxicity with high-resolution comput-
erized tomographic scan. J Cardiovasc Electrophysiol 2001;
12(4):431e6.
[34] Standertskjo¨ld-Nordenstam CG, Wandtke JC, Hood WB,
Zugibe FT, Butler L. Amiodarone pulmonary toxicity. Chest
radiography and CT in asymptomatic patients. Chest 1985;
88(1):143e5.
[35] Vernhet H, Bousquet C, Durand G, Giron J, Senac J. Reversible
amiodarone-induced lung disease: HRCT findings. Eur Radiol
2001;11(9):1697e703.
[36] Owens C, Evans T, Keogh BF, Hansell D. Computed tomography
in established adult respiratory distress syndrome: correlation
with lung injury score. Chest 1994;106:1815e21.
[37] Ichikado K, Suga M, Muranaka H, et al. Prediction of prog-
nosis for acute respiratory distress syndrome with thin-
section CT: validation in 44 cases. Radiology 2006;238(1):
321e9.
[38] Chung JH, Kradin RL, Greene RE, Shepard J-AO,
Digumarthy SR. CT predictors of mortality in pathology
confirmed ARDS. Eur Radiol 2011;21:730e7.
